Carmen S. Yong
YOU?
Author Swipe
View article: 863 A novel bispecific immuno-cytokine therapeutic: ‘switch on’ activity of a conditionally active PD1-IL2v delivering IL2v to PD1+ cells while reducing activity on PD1- cells
863 A novel bispecific immuno-cytokine therapeutic: ‘switch on’ activity of a conditionally active PD1-IL2v delivering IL2v to PD1+ cells while reducing activity on PD1- cells Open
View article: 505 An <i>ex-vivo</i> reverse translational model demonstrates intact T cell functionality independently of clinical response to a T cell bispecific in multiple myeloma patients
505 An <i>ex-vivo</i> reverse translational model demonstrates intact T cell functionality independently of clinical response to a T cell bispecific in multiple myeloma patients Open
View article: IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer
IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer Open
View article: CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer Open
Application of machine learning (ML) on cancer-specific pharmacogenomic datasets shows immense promise for identifying predictive response biomarkers to enable personalized treatment. We introduce CAN-Scan, a precision oncology platform, w…
View article: Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease
Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease Open
Cancer resistance to immune checkpoint inhibitors motivated investigations into leveraging the immunostimulatory properties of radiotherapy to overcome immune evasion and to improve treatment response. However, clinical benefits of radioth…
View article: IL-2 immunotherapy rescues irradiation-induced T cell exhaustion<i>in vivo</i>
IL-2 immunotherapy rescues irradiation-induced T cell exhaustion<i>in vivo</i> Open
Summary Radiotherapy (RT) can stimulate anti-cancer T cell responses that target primary and distant tumors. In addition to antigen-mediated stimulation of effector T cells, signals from stimulatory cytokines, notably interleukin-2 (IL-2),…
View article: Supplementary Movie 4 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 4 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 4. Serial killing of tumor targets by CAR.OT-I effector cells following engagement through the TCR
View article: Supplementary Movie 4 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 4 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 4. Serial killing of tumor targets by CAR.OT-I effector cells following engagement through the TCR
View article: Supplementary Movie 3 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 3 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 3. CAR.OT-I cells co-cultured with MC57-HER2 cells.
View article: Supplementary Movie 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 1. OT-I cells co-cultured with MC57-OVA257 cells.
View article: Supplementary Figure 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Figure 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Figure 1. TCR activated OT-I and CAR. OT-I cells display similar expression levels of cytotoxic granules.
View article: Supplementary Movie 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 2. CAR.OT-I cells co-cultured with MC57-OVA257 cells.
View article: Supplementary Movie 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 1. OT-I cells co-cultured with MC57-OVA257 cells.
View article: Supplementary Movie 5 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 5 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 5. Serial killing of tumor targets by CAR.OT-I effector cells following engagement through the CAR
View article: Supplementary Methods from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Methods from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Methods. Time lapse live video (TLLV) microscopy
View article: Supplementary Movie 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 2. CAR.OT-I cells co-cultured with MC57-OVA257 cells.
View article: Supplementary Movie 3 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 3 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 3. CAR.OT-I cells co-cultured with MC57-HER2 cells.
View article: Supplementary Figure 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Figure 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Figure 2. OVA257 peptide dose does not affect effector cell maturation status.
View article: Supplementary Methods from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Methods from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Methods. Time lapse live video (TLLV) microscopy
View article: Data from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Data from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically. However, there are important aspects of CAR-T-cell biology that have not been explored, particularly with respect to the kinetics of activation, …
View article: Data from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Data from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically. However, there are important aspects of CAR-T-cell biology that have not been explored, particularly with respect to the kinetics of activation, …
View article: Supplementary Figure 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Figure 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Figure 1. TCR activated OT-I and CAR. OT-I cells display similar expression levels of cytotoxic granules.
View article: Supplementary Figure 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Figure 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Supplementary Figure 2. OVA257 peptide dose does not affect effector cell maturation status.
View article: Supplementary Movie 5 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Supplementary Movie 5 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells Open
Movie 5. Serial killing of tumor targets by CAR.OT-I effector cells following engagement through the CAR
View article: Supplementary Figure 2 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Supplementary Figure 2 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
Supplementary Figure 2 - PDF file 20K, Expression of PD-1 is upregulated on CAR T cells following antigen stimulation with e0771-Her2+ tumor cells
View article: Supplementary Figure Legends from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Supplementary Figure Legends from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
Supplementary Figure Legends - PDF file 66K, Supplementary Figure legends
View article: Supplementary Figure 1 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Supplementary Figure 1 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
Supplementary Figure 1 - PDF file 73K, Tumor cells express high levels of PD-L1
View article: upplementary Figure 3 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
upplementary Figure 3 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
upplementary Figure 3 - PDF file 17K, Gr1+ cells express PD-1 and PD-L1
View article: upplementary Figure 3 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
upplementary Figure 3 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
upplementary Figure 3 - PDF file 17K, Gr1+ cells express PD-1 and PD-L1
View article: Supplementary Figure 2 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Supplementary Figure 2 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells Open
Supplementary Figure 2 - PDF file 20K, Expression of PD-1 is upregulated on CAR T cells following antigen stimulation with e0771-Her2+ tumor cells